Compare Neurocrine Biosciences Inc (NBIX) vs Global X NASDAQ 100 Covered Call ETF (QYLD) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Neurocrine Biosciences Inc vs Global X NASDAQ 100 Covered Call ETF — how do they compare? Neurocrine Biosciences Inc trades at $155.85 (market cap $15.77B), while Global X NASDAQ 100 Covered Call ETF trades at $18.35. The key difference: Global X NASDAQ 100 Covered Call ETF is trading nearer its 52-week high, Neurocrine Biosciences Inc nearer its low. Which is the better fit depends on your goals.
| NBIX | QYLD | |
|---|---|---|
Market Cap | $15.77B | — |
Sector | Health | Income / Options Overlay |
52-Week High | $185.50 | $18.52 |
52-Week Low | $123.10 | $16.70 |
Enterprise Value | $15.78B | — |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Neurocrine Biosciences (NBIX) trades at $155.13, down 0.33% with a bearish technical signal. The company maintains strong fundamentals with 97.91% gross margins and 20.91% net income margin, supported by robust Ingrezza sales growth and Crenessity momentum. Recent news highlights institutional buying interest but also safety concerns around Vykat XR, contributing to recent price volatility.
NBIX presents a compelling growth story with strong profitability and analyst support (86% buy rating), though execution risks and drug safety issues warrant caution. The consensus price target of $207.07 suggests 33% upside potential, making it attractive for investors comfortable with biopharma volatility.
QYLD trades at $18.37, up 0.05% with a bullish technical signal from moving averages. The ETF generates income through covered calls on the NASDAQ-100, providing an estimated 11-12% yield but limiting upside participation in strong bull markets. Recent dividend payments of $0.18-$0.19 per share demonstrate consistent income generation while the underlying index experiences volatility.
The outlook remains mixed - QYLD offers attractive monthly income for retirees but has historically underperformed the NASDAQ-100 during sustained rallies. Principal erosion risk exists as the strategy caps gains during market advances. Investors should weigh high yield against potential long-term capital appreciation sacrifice in tech-heavy markets.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
About Neurocrine Biosciences Inc
Neurocrine Biosciences, Inc. is a biopharmaceutical company focused on discovering, developing, and commercializing innovative treatments for neurological, endocrine, and psychiatric disorders. The company's portfolio targets conditions such as tardive dyskinesia, endometriosis, and Parkinson's disease. NBIX leverages its expertise in neurobiology and small-molecule drug development to address diseases with significant unmet medical needs.
Read more on NBIX →About Global X NASDAQ 100 Covered Call ETF
QYLD is an ETF that follows a covered call strategy on the NASDAQ 100 Index. The fund holds a long position in the stocks of the NASDAQ 100 and simultaneously writes (sells) call options on the index. The primary goal is to generate monthly income from the option premiums. This strategy can reduce portfolio volatility and provide income, but it limits potential capital appreciation from a significant rise in the NASDAQ 100 Index.
Read more on QYLD →
